

**October 30, 2024**

To,  
Listing Department  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
Mumbai - 400001  
Script Code – 540737

**Sub: Press Release**

With reference to the captioned subject, we enclose herewith the Press Release with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2024.

Kindly take the same on your record.

Thanking You,

**Yours faithfully,**  
**For Shree Ganesh Remedies Limited**

**Aditya Patel**  
**Company Secretary**

**Enc. a/a**

## SHREE GANESH REMEDIES LIMITED REPORTS Q2 & H1FY25 RESULTS

**Ankleshwar, October 30<sup>th</sup>, 2024: Shree Ganesh Remedies Limited**, one of the fastest growing CMO & CDMO based in India for Pharmaceutical Intermediates & Fine Chemicals, announced its financial results for Q2 & H1FY25.

### Commenting on the results, Mr. Gunjan Kothia, Promoter, Whole-Time Director, said:

*I am pleased to provide you with an update on our performance for Q2FY25. This quarter has proven to be strong for Shree Ganesh Remedies Limited, showcasing robust topline growth and healthy profitability despite a challenging operating environment, particularly due to dampened demand from European markets.*

*Our strategic focus on optimising our product mix has been instrumental in achieving high profitability, and we anticipate this trend will continue into the coming quarter. Although the slowdown in Europe has presented some challenges, we have proactively adjusted our product offerings to compensate for lower sales volumes with higher profitability growth through the year.*

*The newly commissioned Block 8 is currently operating at lower capacity utilisations; however, we are actively engaging with our clients and remain optimistic about ramping up production in the upcoming quarters.*

*With ample land available at our Ankleshwar and Dahej sites, we are well-positioned for future expansion. Our commitment to developing new complex molecules and enhancing our advanced manufacturing capabilities provides a significant runway for growth, ensuring that we continue to deliver value to our stakeholders in the years ahead.*

### Financial Highlights for Quarter Ended September 30<sup>th</sup>, 2024: (₹ In crore & %)

REVENUE  
**32.33 Cr.**  
⬇️ -3% YoY

PAT  
**6.39 Cr.**  
⬇️ -2% YoY

**19.02 Cr.**  
Revenue from Pharma Intermediates in Q2FY25

**21.03 Cr.**  
Revenue from Exports in Q2FY25

EBITDA  
**11.31 Cr.**  
⬆️ 23% YoY

EBITDA MARGINS  
**35.0 %**  
⬆️ 737 BPS YoY

**13.17 Cr.**  
Revenue from Speciality Chemicals in Q2FY25

**11.07 Cr.**  
Revenue from Domestic Sales in Q2FY25

### Financial Highlights for Half Year Ended September 30<sup>th</sup>, 2024: (₹ In crore & %)

REVENUE  
**57.11 Cr.**  
⬇️ -5% YoY

PAT  
**11.07 Cr.**  
⬇️ -2% YoY

**28.81 Cr.**  
Revenue from Pharma Intermediates in H1FY25

**33.01 Cr.**  
Revenue from Exports in H1FY25

EBITDA  
**19.43 Cr.**  
⬆️ 20% YoY

EBITDA MARGINS  
**34.03 %**  
⬆️ 712 BPS YoY

**27.37 Cr.**  
Revenue from Speciality Chemicals in H1FY25

**23.18 Cr.**  
Revenue from Domestic Sales in H1FY25

## Financial Highlights:

PARTICULARS (₹ IN CRORES)	Q2FY24	Q1FY25	Q2FY25	YoY Change	QoQ Change	H1FY24	H1FY25	YoY Change
<b>Revenue from Operations</b>	<b>33.42</b>	<b>24.78</b>	<b>32.33</b>	<b>-3%</b>	<b>30%</b>	<b>60.13</b>	<b>57.11</b>	<b>-5%</b>
Total Income	34.22	25.32	32.52	-5%	28%	61.50	57.84	-6%
Operating Expenses	24.19	16.66	21.02	-13%	26%	43.95	37.68	-14%
<b>EBITDA (Excluding OI &amp; EI)</b>	<b>9.23</b>	<b>8.12</b>	<b>11.31</b>	<b>23%</b>	<b>39%</b>	<b>16.18</b>	<b>19.43</b>	<b>20%</b>
<b>EBITDA %</b>	<b>27.6%</b>	<b>32.8%</b>	<b>35.0%</b>	<b>737 bps</b>	<b>220 bps</b>	<b>26.91%</b>	<b>34.03%</b>	<b>712 bps</b>
Finance Cost	0.01	0.32	0.43	3,353%	36%	0.02	0.74	3,773%
Depreciation & Ammortization	1.41	2.02	2.42	72%	20%	2.45	4.44	82%
PBT	8.61	6.33	8.65	0%	36%	15.08	14.98	-1%
<b>PAT</b>	<b>6.55</b>	<b>4.65</b>	<b>6.39</b>	<b>-2%</b>	<b>37%</b>	<b>11.31</b>	<b>11.07</b>	<b>-2%</b>
EPS (₹)	5.34	3.62	4.98	-7%	38%	9.18	8.60	-6%

## About Shree Ganesh Remedies Limited: (SGRL)

Shree Ganesh Remedies Limited is a leading player in the chemical manufacturing industry, specialising in pharmaceutical intermediates and specialty chemicals. With over 19 years of excellence, the company is renowned for its unparalleled expertise in advanced chemical synthesis and complex chemical reactions. Strategically expanding its operations, Shree Ganesh Remedies is focused on innovation through strategic R&D investments and state-of-the-art infrastructure. The company serves over 20 countries, including key markets in the EU and the US, offering tailored solutions to global industry leaders. Committed to sustainable practices, Shree Ganesh Remedies holds multiple accreditations, including ISO certifications and EcoVadis Bronze. With ongoing expansions at its Ankleshwar and Dahej sites and a strategic shift towards complex niche specialty chemicals, the company is well-positioned for future growth and continues to deliver high-quality, custom manufacturing solutions to its clients.

## Contact us:

**Aditya Patel**  
Company Secretary  
**Shree Ganesh Remedies Limited**  
Email: [investors@ganeshremedies.com](mailto:investors@ganeshremedies.com)

**Abhishek Mehra**  
Investor Relations Advisors  
**TIL Advisors Private Limited**  
Email: [abhishek@theinvestmentlab.in](mailto:abhishek@theinvestmentlab.in)  
Mobile No.: +91 95588 14500

Certain statements in this document that are not historical facts are forward looking statements. Such forward looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Shree Ganesh Remedies Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.